Company profile: Aclaris Therapeutics
1.1 - Company Overview
Company description
- Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
Products and services
- KINect® platform: Proprietary discovery system that identifies novel small-molecule therapeutics by targeting kinases implicated in immuno-inflammatory conditions for kinase-directed drug discovery
- ATI-1777: Soft topical JAK1/JAK3 inhibitor engineered to treat atopic dermatitis and potentially other dermatologic conditions by localized dual JAK blockade
- Clinical Trials: Investigational clinical programs that evaluate safety and efficacy of Aclaris’s therapies for immuno-inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aclaris Therapeutics
Sparrow Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for disorders of corticosteroid excess, including SPI-62, an oral HSD-1 inhibitor designed to reduce intracellular cortisol in conditions like endogenous Cushing’s syndrome and autonomous cortisol secretion, and SPI-47, combining SPI-62 with prednisolone for autoimmune diseases such as polymyalgia rheumatica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sparrow Pharmaceuticals company profile →
Alpine Immune Sciences
HQ: United States
Website
- Description: Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpine Immune Sciences company profile →
Graviton
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
Upstream Bio
HQ: United States
Website
- Description: Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Upstream Bio company profile →
Pandion Therapeutics
HQ: United States
Website
- Description: Provider of bispecific antibody therapeutics, modular proteins, and antibodies for localized immunomodulation at the site of disease, enabling durable, tissue-specific treatment for patients with autoimmune and inflammatory diseases and organ transplants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pandion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aclaris Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aclaris Therapeutics
2.2 - Growth funds investing in similar companies to Aclaris Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aclaris Therapeutics
4.2 - Public trading comparable groups for Aclaris Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →